HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD). Double-masked, multicenter, active-controlled, randomize...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 127; no. 1; p. 72
Main Authors:	Dugel, Pravin U, Koh, Adrian, Ogura, Yuichiro, Jaffe, Glenn J, Schmidt-Erfurth, Ursula, Brown, David M, Gomes, Andre V, Warburton, James, Weichselberger, Andreas, Holz, Frank G
Format:	Journal Article
Language:	English
Published:	United States 01.01.2020
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Double-Blind Method Female Humans Intravitreal Injections Male Middle Aged Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!